Forbes November 19, 2025
Amy Feldman

Profluent has raised $106 million to scale up use of its AI models for biology in drug development and agriculture.

li Madani started thinking about how AI could be programmed for biology in 2020, years before the launch of ChatGPT. The machine learning scientist was working at Salesforce, which that year launched a moonshot project, called ProGen, to design novel proteins with generative AI. “The same architecture used for English, you can use for biological languages like proteins,” he told Forbes.

He left Salesforce in 2022 and teamed up with Alexander Meeske, head of a research lab at the University of Washington, to bring that promise to life. Now, his Emeryville, California-based startup Profluent’s AI models enable scientists to explain...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: AI (Artificial Intelligence), Investments, Technology, Trends
AI-enabled clinical data abstraction: a nurse’s perspective
Contextual AI launches Agent Composer to turn enterprise RAG into production-ready AI agents
OpenAI’s latest product lets you vibe code science
WISeR in 2026: Legal, Compliance, and AI Challenges That Could Reshape Prior Authorization for Skin Substitutes
Dario Amodei warns AI may cause ‘unusually painful’ disruption to jobs

Share Article